Combination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...

The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex halts VX-264 diabetes cell therapy due to poor efficacy in Phase 1/2 study, but continues Phase 3 trial of zimislecel ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

In this Healio exclusive, John B. Buse, MD, PhD, director of the UNC Diabetes Care Center, reflects on the dramatic evolution of type 2 diabetes treatment over the past 15 years.